In vitro evaluation of ceftibuten (7432-S, SCH 39720), a novel orally administered cephalosporin.
7432-S (SCH 39720) was the most active beta-lactam tested against the Enterobacteriaceae, inhibiting 92% of strains at less than or equal to 8.0 micrograms/ml compared to 82%, 65% and 39% of strains inhibited by cefixime, cefuroxime and cefaclor, respectively. 7432-S was also very effective against Haemophilus influenzae (MIC90, less than or equal to 0.25 microgram/ml), Branhamella catarrhalis (MIC90, 4.0 micrograms/ml) and Neisseria meningitidis (MIC90, less than or equal to 0.25 microgram/ml). Serogroup B streptococci and the penicillin-resistant pneumococci were generally less susceptible to 7432-S and comparison cephems than Streptococcus pyogenes or penicillin-susceptible S. pneumoniae isolates. Pseudomonas spp., enterococci, Acinetobacter spp. and Staphylococcus spp. were routinely resistant to 7432-S (MIC50s, greater than or equal to 32 micrograms/ml).
Jones
R N
RN
Clinical Microbiology Institute, Tualatin, Oregon 97062.
Barry
A L
AL
D000284:Administration, Oral; D002433:Cefaclor / Q000494:pharmacology; D020682:Cefixime; D002439:Cefotaxime / Q000031:analogs & derivatives / Q000494:pharmacology; D000077722:Ceftibuten; D002444:Cefuroxime / Q000494:pharmacology; D002506:Cephalexin / Q000494:pharmacology; D002511:Cephalosporins / Q000031:analogs & derivatives* / Q000494:pharmacology; D004755:Enterobacteriaceae / Q000187:drug effects*; D006193:Haemophilus influenzae / Q000187:drug effects; D008826:Microbial Sensitivity Tests; D001936:Moraxella catarrhalis / Q000187:drug effects; D009345:Neisseria meningitidis / Q000187:drug effects; D013291:Streptococcus / Q000187:drug effects
D002511:Cephalosporins; D002433:Cefaclor; D020682:Cefixime; D000077722:Ceftibuten; D002439:Cefotaxime; D002444:Cefuroxime; D002506:Cephalexin